Compound Information | |
---|---|
ID | 130 |
TrivialName | Ginsenoside Rh1 |
Type | PPT |
MF | C₃₆H₆₂O₉ |
MolecularWeight | 638.883 |
IUPACName | (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
m/z | 683.4368 |
Retention Time | 20.94 |
CCS | 275.95 |
Adducts | [M−H+HCOOH]− |
Isomeric SMILES | CC1(C)[C@@H](O[H])CC[C@@]2(C)C1[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@]4(C)C2C[C@@H](O)C5[C@@]4(C)CCC5[C@@](C)(O[H])CC/C=C(C)/C |
Canonical SMILES | CC(C)=CCCC(C)(O)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3C(OC3OC(CO)C(O)C(O)C3O)CC12C |
Source | PG |
Functions | Anti-inflammatory, Improves cognitive performance, hemostatic, Anti-DENV, Hepatoprotective, antitumor activity, inhibits platelet aggregation |
Year | 1979 |
References | |
Structure |
|